grey market peptides retatrutide Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Need advice : I am

Orforgliprons application as a type 2 diabetes treatment will be filed with the FDA later this year

Cardiologists treating patients with atherosclerotic cardiovascular disease are increasingly initiating semaglutide as a cardiovascular risk modifier, adding an estimated 4.8 million new commercial GLP-1 patients annually

Benefits Significant, clinically proven weight loss Reduced risk of Type 2 diabetes, high blood pressure, and cardiovascular disease Non-surgical, once-weekly injection Personalized dosing not a one-size-fits-all approach Physician-supervised by a board-certified plastic surgeon Built-in path to body contouring if needed after weight loss Best candidates for GLP-1 weight loss injections GLP-1 type medications are suitable for adults who: Have a body mass index (BMI) of 30 or higher (obesity) Have a BMI of 27 or higher (overweight) with at least one weight-related condition, such as type 2 diabetes, high blood pressure, or high cholesterol

This produced modest weight loss with minimal side effects